Dr. David S. Dunkin, M.D.
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
5 E 98th St Fl 10, Mount Sinai Faculty Practice
New York, NY 10029
At a glance
- Medical school
- Univ of Calif, San Francisco School of Dentistry (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2005
Licensed in Connecticut since 2005, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Univ of Calif, San Francisco School of Dentistry
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
NY license 240060 -
Pediatrics Physician
CT license 043418 (first issued 2005; inactive) · NY license 240060
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $185 in total to this clinician.
| Genentech USA, Inc. | $125 |
|---|---|
| AbbVie Inc. | $60.45 |
| Food and Beverage | $185 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $218,093 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie Inc. · Recruiting · NCT05995353 - A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company · Recruiting · NCT04844606 - A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease
Janssen Research & Development, LLC - A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Eli Lilly and Company · Completed · NCT05784246 - Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
AbbVie Inc. · Active, not recruiting · NCT05782907 - Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
AbbVie Inc. · Active, not recruiting · NCT06332534 - M16-194 - A Study to Assess Adverse Events Change in Disease Activity and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn s Disease
AbbVie Inc. - A Study to Assess Adverse Events Change in Disease Activity and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn s Disease
AbbVie Inc. - Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.